Day: May 16, 2022

— Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April — — Announced initiation and dosing of first patient in Phase 2 Trial of IOB102-IOB103 in combination with KEYTRUDA® (pembrolizumab) as first line treatment in multi-arm basket trial — — Strong Balance Sheet with ~$188 million Cash Runway to Support Multiple Data readouts into mid-2024 — NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the quarter ended March 31, 2022. “During our first quarter and in recent weeks we continued to advance our promising...

SAN JOSE, Calif., May 16, 2022 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the first quarter ended March 31, 2022. As of March 31, 2022, the Fund’s net assets were approximately $87.4 million, or $12.68 per share, compared with net assets of approximately $94.8 million, or $13.75 per share as of December 31, 2021. As of March 31, 2022, the Fund’s portfolio included public and private securities valued at approximately $82.2 million, or $11.93 per share, which includes approximately $0.01 per share in cash and cash equivalents. Portfolio Summary (as of 3/31/22)Investment Fair Value1,   Fair Valueper Share1,2Equity/Debt Investments $82.19 million   $11.92Cash/Cash...

MURRAY, Utah, May 16, 2022 (GLOBE NEWSWIRE) — This press release corrects a prior version published on April 28, 2022 and is updated to revise the accounting treatment of certain deferred loan acquisition costs when the guaranteed portions of SBA 7(a) loans were sold. Subsequent to issuing the original press release and during the Company’s preparation of its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, the Company determined that it had been incorrectly accounting for such deferred loan acquisition costs. No corrections are required with respect to the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 as filed with the Securities and Exchange Commission on May 16, 2022. In the first quarter of 2021, FinWise Bancorp started paying marketing fees (representing a new expense...

SANTA ANA, Calif., May 16, 2022 (GLOBE NEWSWIRE) — Unrivaled Brands, Inc. (OTCQX: UNRV) (“Unrivaled” or the “Company”), a multi-state vertically integrated company focused on the cannabis sector with operations in California and Oregon, today reported its first quarter 2022 financial results for the quarter ended March 31, 2022. Tiffany Davis, Chief Executive Officer of Unrivaled Brands, stated, “In my recent shareholder letter, I emphasized the importance of a Company’s management and board being able to act swiftly and responsibly to both preserve value and effectively position the organization to capture future growth.  “I further indicated our immediate focus was to protect our performing assets and to firmly plant us on the path to profitability, beginning with the development and execution of a 100-day...

Revenue of $47.2 million, up 57%Gross profit $13.5 million, up 127%Gross margin of 28.6%, up 880 bps LOS ANGELES, May 16, 2022 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (NASDAQ:EGLX; TSX:EGLX), an integrated gaming entertainment company, today announced financial results for the three months ended March 31, 2022 (“Q1 2022”). “2022 is off to a very strong start, led by accelerated revenue growth and substantial margin expansion. Q1 2022 gross profit was particularly strong and effectively equal to Q4 2021 gross profit, despite a strong seasonal difference between the two periods,” commented Adrian Montgomery, CEO of Enthusiast Gaming. “Our flywheel model, centered around communities, content, creators, and experiences, continues to drive increasing value. Our team is well positioned...

Ongoing Phase 1 study of unmodified placental-derived natural killer (NK) cell therapy candidate, CYNK-001, in acute myeloid leukemia (AML) continues enrolling new cohorts to reflect adjustments to treatment regimen and dosing as outlined in December 2021Ongoing Phase 1 study of CYNK-001 in glioblastoma multiforme (GBM) U.S. Food and Drug Administration (FDA) granted Fast Track designation to genetically modified placental-derived NK cell therapy candidate, CYNK-101, in first line metastatic HER2/neu positive gastric and gastroesophageal junction cancers; Phase 1/2a study is ongoing FDA granted an Orphan Drug Designation to CYNK-101 for the treatment of gastric/gastroesophageal junction cancersFLORHAM PARK, N.J., May 16, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a clinical-stage...

Interim data from Part A of RINGSIDE study of AL102 expected mid-2022 REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced first-quarter 2022 financial results and provided a corporate update. “We continued to execute on advancing our clinical programs during the first quarter of 2022,” said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. “Our highest immediate priority is completing Part A of the RINGSIDE study evaluating AL102 in desmoid tumors and we are on target to announce initial interim data around mid-year. This will be followed...

Articulates Four Strategic Imperatives to Accelerate Company Evolution as a Leading Health and Wellness Provider for ‘People on the Go’ Quarterly Revenue of $24.0 Million and Adjusted EBITDA of $0.4 Million Cash Balance of $83.0 Million and No Long-Term Debt Repurchased $11.1 Million of Shares During the First Quarter 2022, Intends to Complete Remaining Repurchase Authorization as Opportunities Arise Webcast and Conference Call Scheduled for 4:30 PM ET Today NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) — XpresSpa Group, Inc. (Nasdaq: XSPA), a travel health and wellness company, today reported that it has filed financial results on Form 10-Q for the first quarter ending March 31, 2022. Scott Milford, XpresSpa Group CEO, stated, “The foundation for the future of our company is built on four strategic imperatives. These imperatives will...

-IND opened for NASH Phase 2a trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist); trial initiated with top-line data expected in second half of 2023 -TERN-601 (GLP-1R agonist) IND-enabling studies underway; Phase 1 clinical trial initiation for obesity expected in 2023 -TERN-701 (allosteric BCR-ABL inhibitor) Phase 1 clinical trial for chronic myeloid leukemia initiated in China -Cash and equivalents of $151 million provides runway into 2025, including three expected clinical trial readouts across three product candidates and three indications FOSTER CITY, Calif., May 16, 2022 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates...